Research Article, J Virol Antivir Res Vol: 5 Issue: 1
Variability and Signatures of Capsid Amino Acid of HIV-1D Subtype from Drug-Naive and ARV-treated Individuals
|Salvatore Dimonte1 and Muhammed Babakir-Mina2*|
|1BioMolecular Lab, Barletta, Italy|
|2Sulaimani Polytechnic University, Sulaimani Governorate, Qirga|
|Corresponding author : Muhammed Babakir-Mina
Sulaimani Polytechnic University, Sulaimani Governorate, Qirga, Wrme StMardin 327, Alley 76, Kurdistan Region of Iraq
|Received: November 12, 2015 Accepted: January 20, 2016 Published: January 26, 2016|
|Citation: Dimonte S, Babakir-Mina M (2016) Variability and Signatures of Capsid Amino Acid of HIV-1 D-Subtype from Drug-Naïve and ARV-treated Individuals. J Virol Antivir Res 5:1. doi:10.4172/2324-8955.1000148|
The infection by the human immunodeficiency virus (HIV) has changed dramatically in recent years from invariably fatal disease to chronic disease. HIV-1 subtype D viruses were first isolated from the peripheral blood lymphocytes in 1983 in patients from the Democratic Republic of the Congo and today this subtype is present mainly in eastern, central and west Africa. There are fewer studies that expansively investigate the HIV-1 subtype D diversity for capsid variability to date thus in this study wanted to analyse and examine the distribution of naturally occurring sequence variability in full-length capsid sequences of HIV-1 subtype D.
The 279 HIV-1 D-subtype capsid sequences from the Los Alamos database were retrieved. From this conspicuous dataset of patients at all stages of infection (one isolate per single patient), 153 were drug-naïve and 126 were drug-treated. Then, the amino acidic variability of capsid sequences was analysed.
In drug-naïve patients, among the 80 capsid variable residues, 27 were mutated in >5 % of patients and 9 of them were highly variable. Consequently, 151 out of 231 capsid amino acid residues were highly conserved (≤1 % variability). While in ARV-treated patients, among the 83 variable residues, 29 were mutated in >5 % of patients, and 11 of them were highly variable. Consequently, 148 out of 231 capsid amino acid residues were highly conserved (≤1 % variability).
Genetic fragility of the HIV-1 capsid may explain why cell-mediated immune responses to Gag link with better prognosis in viral infection, and suggests that viral capsids are the good targets for therapy as well as vaccination strategies. Hence, the variability of the capsid protein of the D-subtype HIV-1 is not widespread, but it is absolutely mandatory to prevent minority species resistant to any new treatment approaches. Also the specific in vitro and/or in vivo studies are needed to establish the role of some signatures here noted. Exploring further the implications such changes may have on drug-resistance may be relevant